Abstract
We measured intracellular accumulation of N-desmethyl imatinib (CGP 74588), the main pharmacologically active metabolite of imatinib (Gleevec or STI-571), in Bcr–Abl-positive cells. Using a sensitive and robust non-radioactive in vitro assay, we observed that CGP74588 accumulates in significantly higher amount than imatinib in sensitive K562 cells. In contrast, the intracellular level of CGP74588 was significantly lower than that of imatinib in K562/Dox cells, which represent a multidrug-resistant variant of K562 cells due to the P-glycoprotein (P-gp, ABCB1, MDR1) overexpression. An in vitro enzyme-based assay provided evidence that CGP74588 might serve as an excellent substrate for P-gp. Accordingly, we found that CGP74588 up to 20 μM concentration neither induced apoptosis nor inhibited substantially cell proliferation in resistant K562/Dox cells. In contrast, CGP74588 was capable to inhibit cell proliferation and induced apoptosis in sensitive K562 cells, although its effect was approximately three to four times lower than that of imatinib in the same cell line. Our results indicate that CGP74588 could hardly positively contribute to the treatment of chronic myeloid leukemia (CML) where ABCB1 gene overexpression represents a possible mechanism of resistance to imatinib in vivo.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ et al (1996) Inhibition of the Abl protein-kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100–104
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanninget S et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561–566
Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925–932
Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G et al (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8:3034–3038
Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M et al (2004) Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44:158–162
Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P et al (2005) Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dospos 33:1503–1512
Ludescher C, Thaler J, Drach D, Drach J, Spitaler M, Gattringer C (1992) Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br J Hematol 82:161–168
Mlejnek P, Novak O, Dolezel P (2011) A non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite in Bcr-Abl positive cells. Talanta (in press)
Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA (1992) Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 267:4854–4858
Mlejnek P, Dolezel P (2010) Induction of apoptosis by A3 adenosine receptor agonist N6-(3-iodobenzyl)-adenosine-5'-N-methylcarboxamide in human leukemia cells: a possible involvement of intracellular mechanism. Acta Physiol 199:171–179
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immun Meth 65:55–63
Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P et al (1992) Cytometry 13:795–808
Hegedus T, Orfi L, Seprodi A, Váradi A, Sarkadi B, Kéri G (2002) Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 1587:318–325
Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101:2368–2373
Tang R, Faussat AM, Perrot JY, Marjanovic Z, Cohen S, Storme T (2008) Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer 8:51–59
Acknowledgment
This work was supported by grant NS/9627-3 (Ministry of Health) and partly by grant MSM 6198959216 (Ministry of Education, Youth, and Sports).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mlejnek, P., Dolezel, P., Faber, E. et al. Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells. Ann Hematol 90, 837–842 (2011). https://doi.org/10.1007/s00277-010-1142-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-010-1142-7